Protalix BioTherapeutics (PLX)
Your Dashboard
Displaying PLX Charts
Personalize your Dashboard. You can add and remove charts, drag and drop them into the order you
like, and we'll save your settings for the next time you visit when you're logged in.
Log in here or Click here to register for your free account.
Select or add more charts
- Accounts Payable 12.87M
- Accounts Receivable 3.969M
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization 0.0099
- Beneish M-Score Pro
- Beta Pro
- Book Value -6.457M
- Book Value per Share -0.0711
- Capital Expenditures 0.81M
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing 25.57M
- Cash Financing TTM 25.56M
- Cash Investing -0.852M
- Cash Investing TTM -4.07M
- Cash Operations -6.281M
- Cash Operations TTM -25.86M
- Cash and Equivalents 45.60M
- Cash and ST Investments 45.60M
- Current Ratio 2.812
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield 0.00%
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share -0.07
- Earnings Per Share Growth
- Earnings Per Share TTM -0.44
- Earnings Yield -7.17%
- Effective Tax Rate TTM Pro
- Enterprise Value 531.10M
- Expenses 9.632M
- Expenses TTM 38.08M
- Free Cash Flow -7.091M
- Free Cash Flow TTM -29.77M
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin 64.59%
- Gross Profit TTM -1.371M
- Income from Cont. Ops Pro
- Interest Expense 0.00
- Interest Income
- Inventories 0.263M
- KZ Index Pro
- Liabilities 74.92M
- Long Term Debt 0.00
- Market Cap 557.63M
- Net Income -5.904M
- Net Income TTM -37.38M
- Net PP&E 17.51M
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price 6.14
- Price / Book Value
- Price / Sales Ratio 801.20
- Price / Tangible Book Value Pro
- Profit Margin -158.4%
- R&D Expense 8.847M
- Receivables Turnover 0.1087
- Retained Earnings -177.88M
- Retained Earnings Growth
- Return on Assets -55.97%
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth -37.87%
- Revenue Per Share TTM 0.0077
- Revenues 3.728M
- Revenues TTM 0.696M
- SG&A Expense 1.629M
- Shareholders Equity -6.457M
- Shares Outstanding 90.82M
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets 68.46M
- Total Return Price 6.14
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
What do these terms mean? Read all about them in the Glossary.
PLX News
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
May 29, 7:30AM GlobeNewswire
May 29, 7:30AM GlobeNewswire
@groberjg07 $ARNA $PLX immediately opened on FDA approval and yet we are still halted..
about 21 days ago by BiopharmaPro
about 21 days ago by BiopharmaPro
$PLX http://stks.co/3lrN recovery after the Approval profit taking, will be volatile till the option expiry 5/19
about 21 days ago by gantosj
about 21 days ago by gantosj
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
May 10, 7:30AM GlobeNewswire
May 10, 7:30AM GlobeNewswire
$PLX pumper article won't save this thing. massive insider selling tells the story. this wont go above 7.5 imo
about 23 days ago by johnkelly
about 23 days ago by johnkelly
well apparantly $PLX insiders dont think it'll go over $7.50 anytime soon! never seen so much selling lol http://stks.co/3iSq
about 23 days ago by johnkelly
about 23 days ago by johnkelly
$VTUS Phase 3 data for anal fissures, expected by May 15th, 120M market share, no competitor, grossly undervalued $JAZZ $PLX $VVUS $$
about 24 days ago by peterumble
about 24 days ago by peterumble
RT @peterumble Short stocks: $EXEL $RGEN $PLX $POZN $CVM , markets hate uncertainty $SPY- SPY down 3.1% POZN up 0.8% since Wed. close. DD.
about 26 days ago by Glopolon
about 26 days ago by Glopolon
$PLX glad i held on..this is going LOW on monday. ceo has NO shares now..dont blame them, i would have done the same
about 27 days ago by gotgame83
about 27 days ago by gotgame83
$PLX why do people think the pfe is going to buy them out? dont they already have a partnership with them? any benefit for pfe?
about 27 days ago by gotgame83
about 27 days ago by gotgame83
$PLX last minute buying ahed of "weekend buyout" comical...
about 27 days ago by johnkelly
about 27 days ago by johnkelly
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential
Apr 19, 9:14AM Street Insider
Apr 19, 9:14AM Street Insider
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Mar 16, 4:01PM GlobeNewswire
Mar 16, 4:01PM GlobeNewswire
Auriga Reiterate a 'Buy' on Protalix BioTherapeutics (PLX); No Material Changes in 10-K
Mar 01, 10:42AM Street Insider
Mar 01, 10:42AM Street Insider
Protalix BioTherapeutics to Participate at Two Upcoming Global Healthcare Conferences
Feb 23, 7:30AM GlobeNewswire
Feb 23, 7:30AM GlobeNewswire
Protalix BioTherapeutics Announces Closing of Public Offering and Exercise of Over-Allotment Option
Feb 22, 4:15PM GlobeNewswire
Feb 22, 4:15PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PLX | 6.14 | -0.21 | -3.31% | 576.71M |
| SONC | 8.28 | +0.01 | +0.12% | 500.75M |
| SON | 30.48 | -0.33 | -1.07% | 3.098B |
| SOMX | 0.30 | +0.01 | +3.45% | 13.95M |
| SOMH | 8.50 | +0.00 | +0.00% | 45.39M |
| SOL | 1.25 | -0.01 | -0.79% | 109.43M |
| SOHU | 43.08 | -1.69 | -3.77% | 1.705B |
| SOFO | 7.200 | -0.00 | -0.00% | 27.72M |
| SNSS | 2.90 | -0.11 | -3.65% | 140.93M |
| SNPS | 29.14 | -0.41 | -1.39% | 4.308B |
